- Provider
- Mochi Health
- Medication starting offer
- As low as $60; dose-dependent
- Membership
- Required; medication excluded
- Product status
- Compounded, not FDA-approved
Keep the injection separate from other menu items
Mochi lists several semaglutide options, including branded and compounded products. This review concerns its dedicated compounded injectable offering. A shared active-ingredient name should not combine those entries into one evidence or price claim.[source]
Ask for the prescribed preparation, pharmacy and instructions. The review cannot determine whether a compounded product is appropriate for an individual.
The medication page explicitly qualifies the price
The product page advertises an as-low-as $60 figure and says price varies by the prescribed dose. It also requires a Mochi membership, whose fee excludes medication.[source]
A fair budget therefore needs the selected dose and membership terms. The current homepage’s promotional annual membership is an upfront commitment, not evidence that all patients pay the same monthly fee.[source]
The branded semaglutide result is not transferable
A clinical trial of Wegovy does not independently establish outcomes for Mochi’s compounded injection. We do not label this product a generic Wegovy equivalent or attach a branded trial’s percentage loss to it.[source]
FDA’s concerns about unapproved GLP-1 versions provide relevant context, including preparation and dosing issues.[source]
Ask how price and care change together
If the clinician changes the prescription, clarify whether the medication charge changes too. Find out who answers side-effect questions and whether additional services or diagnostic testing create separate fees.
This publication did not test member visits or clinical response times. A membership’s advertised features are not a measured service score.
Request a quote that can be compared
Place this selected-plan quote beside CoreAge Rx’s compounded offer with the same billing horizon and clear formulation details. Compare branded Wegovy routes in a separately labeled category. That preserves the difference between a cost comparison and a claim of clinical equivalence.
Sources & further reading
Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Each source has its own last-checked date below.
- Mochi: compounded semaglutideStarting medication quote; dose-dependent; membership extra · Checked October 8, 2026
- Mochi Health: current care modelProvider membership and care overview · Checked October 8, 2026
- Aronne et al., NEJM 2025: tirzepatide compared with semaglutide for obesityPrimary randomized trial abstract; SURMOUNT-5, 751 adults without diabetes, 72 weeks; funded by Eli Lilly · Checked October 8, 2026
- FDA: concerns with unapproved GLP-1 drugsCompounded-product risks, salt forms, dosing errors and online red flags · Checked October 10, 2026